[1] |
JING Tianshu, LU Guotao, WANG Shengfeng.
Risks of Pancreatic Adverse Events Associated with Tirzepatide: a Disproportionality Analysis Using Spontaneous Adverse Event Reporting System Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 669-673.
|
[2] |
LIAO Mengfan, ZHONG Liling, XU Yan, LIU Ying, ZHANG Yexiang, CHEN Qingsong, LIU Xudong.
Adverse Reactions to Antihypertensive and Hypoglycaemic Drugs Based on Spontaneous Presentation Systems
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 286-291.
|
[3] |
YU Wenlu, ZHANG Hong.
Research Progress in Applications of Strychnine Semen in Orthopedics and Traumatology
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 116-120.
|
[4] |
YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen.
One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.
|
[5] |
YU Xin, GONG Leilei, YAO Weijie, YUAN Sisi, FENG Xin.
Chinese patent medicines for recurrent spontaneous abortion: a scoping review of clinical evidence
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 361-365.
|
[6] |
CHEN Liye, ZHU Li, GONG Leilei.
Pharmaceutical care of a patient with type 2 diabetes mellitus treated with a combination of traditional Chinese and Western medicine during acute exacerbation of gout
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 451-453.
|
[7] |
WANG Shan, HUANG Jukai, WU Honghui, WEN Yalu, ZHANG Li, WANG Jianhua, YANG Xiaohui.
Evaluation of a KKAy animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 273-276.
|
[8] |
WEI Anhua, QI Jianjun, WANG Lu, ZENG Lu, GONG Xuepeng, JIANG Ying.
Adverse drug reaction/ event caused by oral antidiabetic drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1415-1420.
|
[9] |
MU Sicong, WANG Zhuo, LU Junyang, JI Liwei, LIU Xin.
Effects of pioglitazone on plasma adiponectin in patients with type 2 diabetes mellitus: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1015-1018.
|
[10] |
YANG Liu, SHI Fenghua, MA Lijuian.
Logistic regression analysis of influencing factors of adverse drug reaction of glimepiride and their effect on treatment of T2DM
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1030-1034.
|
[11] |
ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei.
Analysis of neuropsychiatric adverse reactions caused by zolpidem
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.
|
[12] |
XIANG Yufang, SUN Hui, CHEN Yue, WANG Ningsheng, LUO Shishu, ZHANG Zhi, FENG Bianling.
Medication safety and combined medication in patients with type 2 diabetes mellitus
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 313-316.
|
[13] |
XU Zhe, JU Ping, LUO Qi, YANG Huan, WANG Yang.
930 cases of adverse drug reactions induced by antibacterial drugs in children
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 317-321.
|
[14] |
ZHANG Shuai, GENG Yue, WAN Liyan, JI Liwei.
Efficacy and safety of insulin degludec vs other long-acting basal insulin analogues in the treatment of type 1 diabetes
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1358-1361.
|
[15] |
TANG Yan, WANG Jialin, ZHOU Jingya, ZHAO Weigang, DU Boran, HU Dandan, YANG Liping, YANG Yingying, ZHAO Zhe, YUAN Tao.
Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1376-1379.
|